Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A disintegrin and metalloproteinase domain-like protein decysin-1 (ADAMDEC1) is a unique, secreted metalloprotease belonging to the ADAM (a disintegrin and metalloproteinase) family[1][4][5]. Unlike most ADAMs, ADAMDEC1 lacks a transmembrane domain and cytoplasmic tail, resulting in a soluble, secreted form. It features a rare zinc-binding motif (HEXXHXXGXXD), which confers unusual resistance to classical metalloprotease inhibitors and modulates its substrate specificity and enzymatic activity[1][4][6]. ADAMDEC1 is expressed mainly in cells of the innate immune system (dendritic cells, monocyte-derived macrophages), with predominant localization in the gastrointestinal tract, where it has roles in mucosal immunity and tissue homeostasis[1][4][6]. Its upregulation is observed in specific pathologies, including inflammatory diseases (such as Crohn’s disease and sarcoidosis) and a range of cancers (notably GI tumors and glioblastoma), and it may serve as a context-dependent modulator of inflammation and epithelial defense. Despite strong evidence of proteolytic activity and involvement in cell competition mechanisms, its precise endogenous substrates and full spectrum of physiological functions remain incompletely characterized[1][2][4][5][6].
Proteolysis of specific (but not fully characterized) substrates (e.g., α2-macroglobulin, pro-EGF). Regulation of cellular interactions in immune and epithelial cells (e.g., apical extrusion of transformed cells, possibly independent of enzymatic activity).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on A disintegrin and metalloproteinase domain-like protein decysin-1 (ADAMDEC1).